Why Compare Wegovy 7.2mg vs Mounjaro for Weight Management?
Wegovy 7.2mg vs Mounjaro: Understanding the Real Options
When searching for "Wegovy 7.2mg", it's important to understand that while this higher dose received MHRA approval on 6th January 2026, it's not yet available through UK pharmacies including EverydayMeds. The current maximum licensed dose remains Wegovy 2.4mg for maintenance therapy from week 17 onwards. This creates an interesting comparison point with Mounjaro, which offers higher doses up to 15mg for patients who may need additional support. Both are prescription-only medicines that work through different but complementary pathways in appetite regulation.
The key distinction lies in their mechanisms: Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, which targets both GIP and GLP-1 receptors simultaneously. This dual-action approach of Mounjaro may explain why some patients respond differently to each treatment. Your prescriber can help determine which mechanism might be more suitable for your individual circumstances, particularly if you're considering stepping up from the current Wegovy 2.4mg maintenance dose.
Wegovy 7.2mg Pricing vs Mounjaro: Current UK Costs
While we await Wegovy 7.2mg availability, the current Wegovy 2.4mg maintenance dose costs £209.99 per pen at EverydayMeds. For patients requiring long-term treatment, our Consistency 2.4mg bundle (×2 pens) provides two months' supply for £419.99, whilst the Ultimate Stability Trio (×3 pens) offers three months for £649.99. Returning customers can apply code DOSE25 at checkout to access these established pricing tiers. Mounjaro follows a different pricing structure with six dose strengths from 2.5mg to 15mg, allowing for more granular dose adjustments.
The economic consideration becomes particularly relevant for maintenance therapy, as this is the dose patients typically remain on indefinitely. STEP 5 trial data showed sustained weight management at 2 years on Wegovy 2.4mg maintenance, making the monthly cost a crucial factor in treatment decisions. Both medications require the same clinical assessment process and next-day cold-chain delivery, so the primary cost difference lies in the medication price itself rather than service fees.
Clinical Evidence: Wegovy 7.2mg Potential vs Current Data
The STEP clinical trial programme established Wegovy's efficacy profile using the current dose escalation up to 2.4mg maintenance. In STEP 1, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The STEP 5 extension demonstrated sustained weight management of approximately 15.2% at two years on 2.4mg maintenance therapy.
While clinical data for Wegovy 7.2mg isn't yet publicly available, the MHRA approval suggests additional efficacy potential for patients who may benefit from higher semaglutide doses. This creates an interesting comparison with Mounjaro's existing higher dose options, which are already available and have their own clinical evidence base. Both treatments require careful monitoring and should only be used alongside a reduced-calorie diet and increased physical activity as part of a comprehensive weight management programme.
How Wegovy 7.2mg vs Current Doses Work in Practice
Wegovy works as a GLP-1 receptor agonist, mimicking the natural incretin hormone that signals fullness after eating. The current dose escalation from 0.25mg to 2.4mg allows patients to gradually adapt to the medication's effects whilst minimising potential side effects. The proposed 7.2mg dose would represent a significant increase from the current 2.4mg maintenance level, potentially offering enhanced appetite suppression and satiety signalling. Patients typically inject once weekly using the FlexTouch pen system, with the medication working continuously to reduce appetite and food cravings throughout the week. The higher dose may provide more sustained effects for patients who experience appetite return towards the end of their weekly dosing cycle.
Ordering Process: Wegovy vs Mounjaro Through EverydayMeds
Both Wegovy and Mounjaro follow the same streamlined ordering process through our GPhC-registered pharmacy (#9012878). The journey begins with a 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Our prescribers review your assessment within 3 working days (or 24 hours with express service), ensuring appropriate clinical oversight for these prescription-only medicines. Once approved, both medications are dispatched via next-day delivery using specialist cold-chain packaging to maintain the required 2-8°C temperature throughout transit. This process ensures clinical safety whilst providing convenient access to both treatment options from a single trusted UK pharmacy.
Storage Advantages: Wegovy 7.2mg vs Mounjaro Practical Considerations
One practical advantage of Wegovy over Mounjaro lies in storage flexibility, which becomes particularly relevant for higher-dose, long-term users. Wegovy pens can be stored at room temperature (below 30°C) for up to 6 weeks once removed from refrigeration, compared to Mounjaro's 21-day room temperature limit. This extended stability makes Wegovy more suitable for frequent travellers or patients with inconsistent refrigerator access. Both medications require initial refrigerated storage at 2-8°C, but Wegovy's superior room temperature stability could be particularly valuable for patients who might eventually use the higher 7.2mg dose, as any wastage due to storage issues becomes more costly at higher dose levels. The FlexTouch pen design remains consistent across all Wegovy doses, ensuring familiar administration techniques.
Wegovy 7.2mg Future Availability vs Current Mounjaro Options
The approval of Wegovy 7.2mg creates an interesting dynamic in the UK weight management landscape, particularly for patients who have reached the current 2.4mg maintenance dose but may benefit from additional support. Currently, these patients might consider switching to Mounjaro's higher dose options, which offer incremental increases up to 15mg. However, the future availability of Wegovy 7.2mg may provide an alternative pathway for dose optimisation within the same medication family. This could be particularly relevant for patients who respond well to semaglutide's specific GLP-1 mechanism but need enhanced potency.
From a clinical perspective, having both options available through EverydayMeds allows for personalised treatment approaches based on individual response patterns and tolerability profiles. Some patients may prefer the familiarity of continuing with semaglutide at a higher dose, whilst others might benefit from switching to tirzepatide's dual-receptor mechanism. The key advantage is having access to both pathways through the same trusted pharmacy, ensuring continuity of care and consistent clinical oversight regardless of which treatment evolution best suits your circumstances.
Making Your Choice: Wegovy 7.2mg vs Mounjaro Consultation
The decision between current Wegovy dosing, future Wegovy 7.2mg availability, or switching to Mounjaro requires careful consideration with your prescriber. EverydayMeds' clinical team can guide you through the assessment process for either medication, ensuring you receive the most appropriate treatment for your individual circumstances. Both are prescription-only medicines requiring ongoing medical supervision, particularly when considering dose adjustments or medication switches. Use code DOSE25 for returning customers, or FIRST40 for new patients beginning their weight management journey. Visit https://everydaymeds.co.uk/collections/weight-loss to begin your clinical assessment and explore both Wegovy and Mounjaro options through our secure, MHRA-compliant service. Remember, successful weight management is a long-term commitment, and we're here to support your journey with consistent, professional pharmaceutical care.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
